excluded by pulmonary angiography. Within 12 hours he had fully recovered. (2) A 39-year-old man with Wolff-Parkinson-White syndrome presented in rapid atrial fibrillation. After disopyramide 300 mg by mouth he developed severe hypotension, cyanosis, raised JVP, and severe epigastric pain. Mesenteric embolus and infarction were diagnosed and an emergency laparotomy was performed. While anaesthetised he developed asystole and could not be resuscitated. No intra-abdominal lesion was found at necropsy.

Comment

Initially we gave 400 mg disopyramide by mouth to revert supraventricular tachycardia with good results.2 After our first two cases of collapse we reduced the initial loading dose of disopyramide to 300 mg. We used loading doses because they have been recommended for disopyramide (after acute myocardial infarction)3 and other antiarrhythmic drugs in order to achieve therapeutic blood concentrations rapidly. Recommended daily maintenance doses of disopyramide vary between 300 and 800 mg.4 Doses ranging from 250 to 400 mg six hourly have been used for ventricular tachycardia.

In our five cases symptoms appeared when maximum serum concentrations would be expected. The serum disopyramide concentration was measured only in the fifth patient: at 6 mg/l it was only slightly above the usually accepted therapeutic range. The adverse effects may have resulted from using standard doses of disopyramide in the presence of myocardial dysfunction or beta adrenoreceptor antagonists, or both. The abdominal pain in four patients was unusual. It was severe and usually epigastric, and in one patient suggested mesenteric embolus and infarction. Its cause remains unexplained. Acute hepatic congestion from cardiac failure was considered but it was found only in one of two patients who had necropsies, and in neither was any other intra-abdominal lesion found. Two patients had ventricular tachycardia. In one it was probably secondary to the use of sympathomimetic agents but in the other it was noted at the time of collapse without any record of

abdominal pain. In both it responded to antiarrhythmic therapy, although respiratory depression and impairment of consciousness followed. The sequence of events is similar to that described in cases of fatal overdosage of disopyramide.⁵ Atypical ventricular tachycardia or self-terminating episodes of ventricular fibrillation during disopyramide administration have been reported and we have also seen this on two other occasions.

All our patients had enlargement of the heart with or without overt cardiac failure, two had myocardial ischaemia, and three were also taking beta-adrenoreceptor blocking drugs. Disopyramide should therefore be used with great care in patients who have myocardial dysfunction or who are taking other negative inotropic drugs. At present we recommend that they should not be given loading doses of 300-400 mg.

⁵ Hayler, A. M, et al, Lancet, 1978, 1, 968.

(Accepted 17 October 1979)

Department of Cardiology, Royal Melbourne Hospital, Victoria 3050, Australia

E G MANOLAS, мв, registrar D HUNT, MD, FRACP, assistant director J T DOWLING, MB, FRACP, assistant director M LUXTON, MD, FRACP, physician J K VOHRA, MD, MRCP, assistant physician G SLOMAN, FRCP, FACC, director

Clinical details in five cases of collapse after taking oral disopyramide

Case No		Weight (kg)	Diagnosis	Arrhythmia	Chest radiograph before collapse		Disopyramide dose (mg)	Time from last dose to collapse	Abdomina	l Outcome
	and sex				Cardiomegaly p	oulm congestion	dose (flig)	(min)	pain	Outcome
1	67 M	76	Myocardial ischaemia	Atrial flutter	Yes	Yes	400 (single dose)	90	Yes	Recovery
2	66 M	63	Myocardial ischaemia	Atrial flutter	Yes	No	400 (single dose)*	90	No	Recovery
3	39 M	107	WPW syndrome	Atrial fibrillation	Yes	Yes	300 (single dose)†	60	Yes	Death
4	54 F	51	Aortic valve replacement	Atrial fibrillation	Yes	No	300† 200 (3½ h later)†	60–120	Yes	Death
5	60 M	66	WPW syndrome	Atrial flutter	Yes	Yes	200 (thrice daily)*	150‡	Yes	Recovered

Vancouver style

All manuscripts submitted to the BMJ from now on should conform to the uniform requirements for manuscripts submitted to biomedical journals (known as the Vancouver style).

The BMJ, together with many other international biomedical journals, has agreed to accept articles prepared in accordance with the Vancouver style and will be introducing the system from January 1980. The style (described in full in BMJ, 24 February, p 532) is intended to standardise requirements for authors and covers text format, presentation of methods and results, use of SI units, and the form of tables and illustrations. All the participating journals have also agreed to introduce a standard form of references.

In future references to papers submitted to the BMJ should include: the names of all authors if there are fewer than seven or, if there are more, the first three followed by et al; the title of journal articles or book chapters; the titles of journals abbreviated

according to the style of Index Medicus; and the first and final page numbers of the article or chapter.

Examples of common forms of references are:

- ¹ International Steering Committee of Medical Editors. Uniform requirements for manuscripts submitted to biomedical journals. Br Med J 1979;1:532-5.
- ² Soter NA, Wasserman SI, Austen KF. Cold urticaria: release into the circulation of histamine and eosinophil chemotactic factor of anaphylaxis during cold challenge. N Engl J Med 1976; 294:687-90.
- Weinstein L, Swartz MN. Pathogenic properties of invading microorganisms. In: Sodeman WA Jr, Sodeman WA, eds. Pathologic physiology: mechanisms of disease. Philadelphia: W B Saunders,

Up to the beginning of October some 100 journals had agreed to accept articles in the Vancouver style, and a full list will be printed early in 1980.

¹ Vismara, L A, et al, Journal of Clinical Pharmacology and Therapeutics, 1974, **16,** 330.

² Sloman, J G, et al, Medical Journal of Australia, 1977, 1, 176.
³ Ward, J W, and Kinghorn, G R, Journal of Internal Medical Research, 1976, **4**, (1), 49.

⁴ Niarchos, A P, American Heart Journal, 1976, 92, (1), 57.

^{*}Ventricular tachycardia during collapse. †Also taking beta-adrenoreceptor blocking drugs. †Serum disopyramide concentration 6 mg/l. WPW = Wolff-Parkinson-White syndrome.